Familial HypercholesterolemiaNCT03900169
Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci
An observational study of Familial Hypercholesterolemia, run by Assiut University at 1 site in Egypt.
Trial summary
Famulial hypercolerstremia as risk factor Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Familial Hypercholesterolemia
- What is being tested?
- Genetic
- How many people
- 2 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2020to 1 Nov 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Stemi patient
Who may be able to join
- -all patient that underwent Ppci
Who cannot join
- Previous ischemic patient
- Patient with raised renal chemistry
- Patient for CABG
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Familial Hypercoleresremia as Risk Factor in Stemi Patient Underwent Ppci
Famulial hypercolerstremia as risk factor
Read the detailed description
Familial hypercolerestremia ad risk factor in stemi patient who underwent Ppci
- Conditions
- Familial Hypercholesterolemia
- Being tested
- Genetic
- Medical subject headings
- Hyperlipoproteinemia Type II
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GeneticGenetic
Lipid profile
| Study group | Role | What they receive |
|---|---|---|
| Stemi patient | Stemi patient who underwent Ppci Receives: Genetic: Genetic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
Measured: One year
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2019
- Study start1 Nov 2020
- Primary completion1 Aug 2021 (estimated)
- Study completion1 Nov 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Familial HypercholesterolemiaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 2 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amira Harby, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03900169
- Sponsor's protocol ID
- Familial hypercolerstremia
- Status last verified
- Jun 2021
- First submitted
- 25 Mar 2019
- Last updated
- 7 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Familial Hypercoleresremia as Risk Factor in Stemi Patient Underwent Ppci
- ClinicalTrials.gov ID
- NCT03900169
- Acronym / sponsor ID
- Familial hypercolerstremia
- Conditions
- Familial Hypercholesterolemia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Nov 2020 (actual)
- Primary completion
- 1 Aug 2021 (estimated)
- Study completion
- 1 Nov 2021 (estimated)
- First posted
- 2 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Famulial hypercolerstremia as risk factor
Detailed description
Familial hypercolerestremia ad risk factor in stemi patient who underwent Ppci
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Stemi patient | – | Genetic: GeneticStemi patient who underwent Ppci |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Stemi patient
Key inclusion criteria (1 listed)
- -all patient that underwent Ppci
Key exclusion criteria (3 listed)
- Previous ischemic patient
- Patient with raised renal chemistry
- Patient for CABG
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GeneticLipid profile | Genetic | Stemi patient |
Primary outcome
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
Time frame: One year
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
Time frame: One year
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2021.
Related trials for Familial Hypercholesterolemia
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Not yet recruiting
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
Familial Hypercholesterolemia
Not yet recruitingObservational study
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
Hypercholesterolaemia, Familial Hypercholesterolaemia
Active, not recruitingObservational study
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE)
Active, not recruitingObservational study
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Familial Hypercholesterolemia, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between familial hypercolerstremia and prognosis of patients in PPCI (time frame: One year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2021.